Holiday Inn, Bratislava, Slovakia

10 th October 2015

Slovak

Podujatie bude ohodnotené CME kreditmi

3 € (platba na mieste možná len v hotovosti)

Pre účastníkov je ubytovanie zabezpečené v mieste konania, hotel Holiday Inn, Bratislava www.holidayinn.sk.

• dvojlôžková izba – 99 €

(cena je uvedená s DPH, zahŕňa ubytovanie, raňajky, miestny poplatok 1,65 €)*

Ubytovanie je možné rezervovať prostredníctvom organizátora podujatia písomnou formou – prihláška na ubytovanie je súčasťou prihlášky na účasť a registračného formulára.

Rezervácia je záväzná, zmena bola možná bez účtovania storno poplatku do 9. 9. 2015.
Po tomto termíne sa o možnostiach ubytovania informujte u organizátora.

Odborný program

8.00 – 8.30 Registration

8.30 – 8.35 Welcome

President of Slovak Oncology Society, Tomáš Šálek

I. Breast Cancer Session

Chairmen: Mária Wagnerová, Stanislav Špánik (8.35 – 9.35)

8.35 – 8.55 1. Breast Cancer – HER2/ER+ (Eva Oravcová, NOÚ Bratislava)

1. Primary results, NRG Oncology/NSABP B-35: A clinical
   trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS
   undergoing lumpectomy plus radiotherapy. (Richard G. Margolese)
2. Neratinib after adjuvant chemotherapy and trastuzumab
   in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3,
   randomized, placebo-controlled trial (ExteNET). (Arlene Chan)
3. Adjuvant denosumab in breast cancer: Results from 3,425
   postmenopausal patients of the ABCSG-18 trial. (Michael Gnat)
4. A double-blind, phase III trial of fulvestrant
   with or without palbociclib in pre- and post-menopausal women with hormone
   receptor-positive, HER2-negative metastatic breast cancer that progressed on prior
   endocrine therapy. (Nicholas C. Turner)
5. Phase III, randomized study of trastuzumab emtansine
   (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for fi rst-line treatment of
   HER2-positive MBC: Primary results from the MARIANNE study. (Paul Anthony Ellis)
6. Phase III trial of etirinotecan pegol (EP) versus Treatment
   of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose
   disease has progressed following anthracycline (A), taxane (T) and capecitabine (C):
   The BEACON study. (Edith A. Perez)

8.55 – 9.15 2. Breast Cancer – Triple-Negative/Local Therapy (Bibiana Vertáková-Krakovská, OÚSA Bratislava)

1. Low-dose oral cyclophosphamide-methotrexate
   maintenance (CMM) for receptor-negative early breast cancer (BC). (Marco Colleoni)
2. Results from a phase 2 study of enzalutamide (ENZA), an
   androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer
   (TNBC). (Tiffany A. Traina)
3. Relationship of omission of adjuvant radiotherapy to
   outcomes of locoregional control and disease-free survival in patients with or
   without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on
   3481 patients from the Gepar-trials. (David Krug)
4. The survival benefi t off ered by the surgical management of
   low-grade ductal carcinoma in situ of the breast. (Yasuaki Sagara)

9.15 – 9.35 Discussion

II. Genitourinary Cancer / Gynecologic Cancer Session

Chairmen: Vladimír Malec, Jozef Mardiak

(9.35 – 10.45)

9.35 – 9.55 3. Genitourinary Cancer (Michal Mego, NOÚ Bratislava)

1. Docetaxel and/or zoledronic acid for hormone-naive
   prostate cancer: First overall survival results from STAMPEDE (NCT00268476).
   (Nicholas David James)
2. A phase III protocol of androgen suppression (AS)
   and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with
   docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).
   (Howard M. Sadler)
3. Interest of short hormonotherapy (HT) associated with
   radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical
   prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—
   NCT00423475. (Christian Carrie)
4. TROG 03.06 and VCOG PR 01-03: The “timing of androgen
   deprivation therapy in prostate cancer patients with a rising PSA (TOAD)”
   collaborative randomised phase III trial. (Gillian M. Duchesne)
5. Defining a molecular subclass of treatment resistant
   prostate cancer. (Himisha Beltran)
6. First-line randomized phase II study of gemcitabine/
   cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The
   International Borealis-1 trial. (Joaquim Bellmunt)
7. A phase II/III, double-blind, randomized trial comparing
   maintenance lapatinib versus placebo after fi rst line chemotherapy in HER1/2
   positive metastatic bladder cancer patients. (Thomas Powles)
8. Randomized phase II, three-arm trial of lenvatinib (LEN),
   everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma
   (mRCC). (Robert Motzer)
9. Final clinical results of a randomized phase II international
   trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell
   carcinoma (ASPEN). (Andrew J. Armstrong)

9.55 – 10.15 4. Gynecologic Cancer (Jozef Šufliarsky, NOÚ Bratislava)

1. A randomized phase II study of paclitaxel/carboplatin/
   bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/
   bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent
   endometrial cancer, GOG-86P. (Carol Aghajanian)
2. Results of ARIEL2: a Phase 2 trial to prospectively identify
   ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.
   (Iain A. McNeish)
3. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in
   patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib,
   open-label expansion trial. (Mary L. Disis)
4. CT perfusion as an early biomarker of treatment effi cacy in
   advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study. (Ting-Yim Lee)

10.15 – 10.45 Discussion

10.45 – 11.00 Coffee-Break**text**

III. Head&Neck Cancer / Melanoma&Skin Cancers Session

Chairmen: Juraj Beniak, Dagmar Sorkovská (11.00 – 12.00)

11.00 – 11.20 5. Head&Neck Cancer (Marek Marinčák, VOÚ Košice)

1. Elective versus therapeutic neck dissection in the clinically
   node negative early oral cancer: A randomised control trial (RCT). (Anil D’Cruz)
2. Phase III randomized trial of standard fractionation
   radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation
   radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally
   advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical
   Trials Group HN.6 trial. (Lillian L. Siu)
3. Antitumor activity and safety of pembrolizumab in
   patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN):
   Preliminary results from KEYNOTE-012 expansion cohort. (Tanguy Y. Seiwert)
4. Prognostic implication of persistent HPV16 DNA detection in
   oral rinses for HPV-positive oropharyngeal carcinoma. (Eleni Marie Rettig)
5. PET-NECK: A multi-centre, randomized, phase III, controlled
   trial (RCT) comparing PETCT guided active surveillance with planned neck
   dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients
   with head and neck squamous cell cancer (HNSCC) treated with primary radical
   chemoradiotherapy (CRT). (Hisham Mohamed Mehanna)

11.20 – 11.40 6. Melanoma&Skin Cancers (Zuzana Pribulová, VOÚ Košice)

1. Efficacy and safety results from a phase III trial of nivolumab
   (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive
   patients (pts) with advanced melanoma (MEL) (CheckMate 067). (Jedd D. Wolchok)
2. Overall survival in COMBI-d, a randomized, double-blinded,
   phase III study comparing the combination of dabrafenib and trametinib with
   dabrafenib and placebo as fi rst-line therapy in patients (pts) with unresectable or
   metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (Georgina V. Long)
3. Long term follow up of survival in a randomised trial of wide
   or narrow excision margins in high risk primary melanoma. (Andrew J Hayes)
4. Survival of SLNB-positive melanoma patients with and
   without complete lymph node dissection: A multicenter, randomized DECOG trial.
   (Ulrike Leiter)
5. Oral nicotinamide to reduce actinic cancer: A phase 3
   double-blind randomized controlled trial. (Andrew James Martin)

11.40 – 12.00 Discussion

12.00 – 13.30 Lunch

IV. Lung Cancer&Mesothelioma / Patient and Survivor Care Session

Chairmen: Peter Beržinec, Jozef Chovanec (13.30 – 14.40)

13.30 – 13.50 7. Patient and Survivor Care (Oľga Szegheöová, FN Nové Zámky)

1. Reduction in late mortality among 5-year survivors of
   childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). (Gregory
   T. Armstrong)
2. Phase III trials of anamorelin in patients with advanced nonsmall
   cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). (Jennifer S. Temel)
3. CALGB 70604 (Alliance): A randomized phase III study of
   standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.
   (Andrew Louis Himelstein)
4. Chemotherapy-related cognitive impairment (CRCI), and
   neurotransmitter signaling, longevity, and infl ammation pathways in 366 breast
   cancer (BC) patients and 366 age-matched cancer-free controls: A prospective,
   nationwide, longitudinal URCC NCORP study. (Michelle Christine Janelsins)
5. Long-term safety of fertility preservation by ovarian
   stimulation and concurrent aromatase inhibitor treatment in women with breast
   cancer. (Kutluk Oktay)

13.50 – 14.20 8. Lung Cancer&Mesothelioma (Gabriela Chowaniecová, ŠN sv. Svorada Nitra)

1. NCCTG N0574 (Alliance): A phase III randomized trial of
   whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients
   with 1 to 3 brain metastases. (Paul D. Brown)
2. Whole brain radiotherapy for brain metastases from nonsmall
   lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK
   Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). (Paula
   Mary Mulvenna)
3. Phase III, randomized trial (CheckMate 057) of nivolumab
   (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small
   cell lung cancer (NSCLC). (Luis Paz-Ares)
4. Efficacy of rociletinib (CO-1686) in plasma-genotyped
   T790M-positive non-small cell lung cancer (NSCLC) patients (pts). (Lecia V. Sequist)
5. Interim results of a phase II study of the BRAF inhibitor
   (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in
   patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer
   (NSCLC). (David Planchard)
6. Efficacy, safety and predictive biomarker results from
   a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC
   (POPLAR). (Alexander I. Spira)
7. Pembrolizumab (MK-3475) in patients (pts) with extensivestage
   small cell lung cancer (SCLC): Preliminary safety and effi cacy results from
   KEYNOTE-028. (Patrick Alexander Ott)
8. Phase I/II study of nivolumab with or without ipilimumab for
   treatment of recurrent small cell lung cancer (SCLC): CA209-032. (Scott Joseph Antonia)
9. Final overall survival (OS) results of the phase III PROCLAIM
   trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation
   therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally
   advanced nonsquamous non-small cell lung cancer (nsNSCLC). (Suresh Senan)
10. Randomized phase III trial of customized adjuvant
    chemotherapy (CT) according BRCA-1 expression levels in patients with node positive
    resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial
    (Eudract:2007-000067-15; NCTgov: 00478699). (Bartomeu Massuti)
11. Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP)
    triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the
    IFCT-GFPC-0701 MAPS randomized phase 3 trial. (Gerard Zalcman)

14.20 – 14.40 Discussion

14.40 – 14.55 Coffee-Break

V. Gastrointestinal Cancer Session

Chairmen: Tomáš Šálek, Igor Andrašina (14.55 – 15.55)

14.55 – 15.15 9. Gastrointestinal cancer (Colorectal) (Marián Kakalejčík, POKO Poprad)

1. A multi-center randomized controlled trial of mFOLFOX6
   with or without radiation in neoadjuvant treatment of local advanced rectal cancer
   (FOWARC study): Preliminary results. (Yanhong Deng)
2. Radiofrequency ablation (RFA) combined with
   chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term
   survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM
   Intergroup 40004 (CLOCC). (Theo Ruers)
3. SIRFLOX: Randomized phase III trial comparing fi rst-line
   mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation
   therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
   (Peter Gibbs)
4. Vitamin D status and survival of metastatic colorectal
   cancer patients: Results from CALGB/SWOG 80405 (Alliance). (Kimmie Ng)
5. Impact of aspirin as secondary prevention in an
   unselected cohort of 25,644 patients with colorectal cancer: A population-based
   study. (Simer Bains)

15.15 – 15.35 10. Gastrointestinal (Non-Colorectal) Cancer (Branislav Bystrický, FNsP Trenčín)

1. Phase III, randomized, double-blind, multicenter, placebo
   (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine
   (ECX) as fi rst-line therapy in patients (pts) with advanced MET-positive (pos) gastric or
   gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. (David Cunningham)
2. Relationship between PD-L1 expression and clinical
   outcomes in patients with advanced gastric cancer treated with the anti-PD-1
   monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. (Yung-Jue Bang)
3. Randomized phase II study of everolimus (E) versus
   everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or
   metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
   (Matthew H. Kulke)

15.35 – 15.55 Discussion

15.55 – 16.00 Closing remarks

President of Slovak Oncology Society, Tomáš Šálek

FAREWELL

SOLEN, s.r.o.

Ambrova 5, 831 01 Bratislava

Tel. 02/5413 1365

fax: 02/ 5465 1384

e-mail: kongres@solen.sk

www.solen.sk

kongres@solen.sk

Ing. Monika Liedlová, liedlova@solen.sk